TITLE

Patent Losses To Create Big Opportunities

PUB. DATE
February 2011
SOURCE
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p65
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article presents the EvaluatePharma report which highlights the challenges that confront the innovator drug industry and the opportunities awaiting the generics drug sector, and shows that 13 blockbuster drugs will lose patent protection in 2013 in the U.S.
ACCESSION #
59994645

 

Related Articles

  • Betting on biogenerics. Dove, Alan // Nature Biotechnology;Feb2001, Vol. 19 Issue 2, p117 

    Focuses on the decision taken by the pharmaceutical industry to manufacture own versions of generic drugs. Reason for the industry's decision; Scope of the drug manufacturing business in the global market; Steps to be taken by manufacturers to produce generic drugs similar to branded drugs;...

  • Generics. Marsh, Peter // BMJ: British Medical Journal (International Edition);12/2/89, Vol. 299 Issue 6712, p1357 

    Focuses on the dispute in the drug industry between the research based pharmaceutical companies and smaller groups for product patents. Action of the research groups for generic prescription; Argument of the research groups over the government policy; Explanation of the factors of anguish to...

  • Patents hold no guarantee in new generics marketplace. Kirsche, Michelle L. // Drug Store News;11/17/2003, Vol. 25 Issue 16, p26 

    Reports that patents hold no guarantee as generic drugs take a larger share of the pharmaceutical industry. Major branded drugs that lost patent protection in 2002; List of top 10 generics companies by prescription; Advantages of early patent legal challenges; Campaign to reduce regulatory...

  • FILLING THE PHARMA PIPELINE.  // Chemistry in Australia;Dec2011, Vol. 78 Issue 11, p9 

    The article reveals that a number of blockbuster patents will expire and generic pharmaceuticals will win market share from the originator pharmaceutical companies in Australia in 2012.

  • Branded drug companies' future pain spells big gains for generic drug makers. West, Diane // Drug Store News;03/04/2002, Vol. 24 Issue 3, p28 

    Reports on the business opportunity of generic drug makers from brand name prescription drugs' patent protection loss by 2005, according to the report, 'The Generics Industry in 2005: A New Threat to Pharma.' One tactic of generic makers to stay on top; Cost of going after high-ticket drugs;...

  • Pharma patent settlements in EU continue to rise.  // PharmacoEconomics & Outcomes News;Dec2013, Issue 693, p10 

    The article reports on the findings of a survey by the European Commission which shows an increase in the number of patent settlement agreements between originator and generic companies in 2012 which has reached 1883, up 120 in 2011.

  • Generics enter 'Golden Age,' but hurdles remain. Baltazar, Amanda // Drug Store News;8/13/2007, Vol. 29 Issue 10, p87 

    The article focuses on the challenges faced by generic drug manufacturers despite the growing opportunities presented to them by patent expirations of drugs manufactured by big firms in the U.S. One outcome of the opportunities for generic drug makers is a diminishing number of firms in the U.S....

  • Patent-extending tactics trouble generics makers. Chater, Amanda // Drug Store News;8/28/2006, Vol. 28 Issue 10, p56 

    The article provides an overview of the performance of the generic drug industry in the United States. It describes the impact of the expirations of branded drugs' patents on the industry. Generic drug sales increased by 20.6 percent to $22.3 billion in 2005. It is estimated that $64 billion...

  • Authorized generics debate continues.  // Drug Store News;8/28/2006, Vol. 28 Issue 10, p60 

    The article reports on the controversy over the issue of authorized generic drugs in the United States. According to the article, authorized generic drugs are those that are made by a branded drug company launched to coincide with the loss of a patent of one of their own products. To manufacture...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics